JOURNAL OF IMMUNOTHERAPY, published by Lippincott Williams & Wilkins, is a premier journal dedicated to advancing the field of immunotherapy, a vital aspect of contemporary cancer research and treatment. With an ISSN of 1524-9557 and an E-ISSN of 1537-4513, this esteemed journal has been disseminating cutting-edge research since 1991 and continues to thrive with a convergence of knowledge leading into 2024. Recognized in the top Q2 quartile for fields such as Cancer Research, Immunology, and Allergy, as well as achieving a Q1 ranking in Pharmacology, the journal serves as a critical resource for researchers, clinicians, and students alike. Its robust impact is reflected in its competitive Scopus rankings across various categories, where it holds significant percentile standings. Highly regarded in the academic community for its rigor, the JOURNAL OF IMMUNOTHERAPY aims to provide a platform for innovative ideas, clinical findings, and experimental research that propels the science of immunotherapy forward. Although it does not offer open access, the journal ensures that its contents remain accessible and impactful for professionals in the field, fostering collaboration and knowledge exchange in an era where immunotherapy holds the promise for breakthroughs in patient care.

Immunopharmacology and Immunotoxicology, published by Taylor & Francis Ltd, is a distinguished academic journal with a focus on the interrelation between pharmacology, immunology, and toxicology. Established in 1978, the journal serves as a vital platform for the dissemination of cutting-edge research aimed at enhancing the understanding of immunologically mediated drug responses and toxic effects. The journal encompasses a broad scope of topics relevant to the fields of immunology, pharmacology, and toxicology, offering insights that are pivotal for both academia and the pharmaceutical industry. With a commendable 2023 impact factor and ranking in Q3 in Immunology and Q2 in both Pharmacology and Toxicology, it holds a respected position within its categories, making it a valuable resource for researchers, professionals, and students seeking to stay abreast of the latest developments in the field. The journal is accessible through traditional subscription models and encourages submissions that bring forth innovative findings that might influence therapeutic strategies and public health.

Journal for ImmunoTherapy of Cancer, published by the esteemed BMJ Publishing Group, is a leading scholarly journal dedicated to advancing the field of immuno-oncology. Since its inception in 2013, this Open Access journal has emerged as a pivotal platform for disseminating cutting-edge research and innovative methodologies in cancer immunotherapy. With a remarkable impact factor and stellar rankings, including Q1 listings in multiple relevant categories such as Cancer Research, Immunology, and Molecular Medicine, it plays a crucial role in bridging the gap between basic immunology and clinical applications, thus fostering collaboration among researchers, healthcare professionals, and students. The journal's scope encompasses a diverse range of topics, focusing on the latest breakthroughs and experimental findings in cancer treatment, making it indispensable for those seeking to contribute to the evolving landscape of oncological sciences. Located in the United Kingdom at the British Medical Association House, the journal continues to serve as a valuable resource for those at the forefront of cancer research and therapy.

BIODRUGS is a prestigious academic journal published by ADIS INT LTD, specializing in the rapidly evolving fields of biotechnology, pharmacology, and medicine. Since its inception in 1997, this journal has established itself as a pivotal platform for disseminating cutting-edge research and comprehensive reviews that address both fundamental and clinical aspects of biopharmaceuticals. With an impressive impact factor and categorized within the prestigious Q1 quartile across multiple disciplines, including pharmacology and biotechnology, BIODRUGS ranks among the top in its field, reflecting its significant contributions to advancing knowledge. The journal's commitment to providing open access facilitates broad dissemination of its content, ensuring that researchers, professionals, and students can easily access critical insights and novel findings. The journal's scope extends well into 2024 and beyond, promising ongoing relevance and a continuous source of insightful academic discourse.

The Journal of Gene Medicine, published by Wiley, stands as a pivotal resource in the field of gene therapy and molecular medicine, with a rich history of dissemination of impactful research since its inception in 1998. With an ISSN of 1099-498X and an E-ISSN of 1521-2254, this esteemed journal plays a crucial role in advancing our understanding of genetics and drug discovery, reflected in its impressive 2023 Scopus rankings where it holds a Q2 classification in Drug Discovery and Q3 in several genetics-related categories. The journal aims to facilitate the exchange of high-quality research findings that bridge the gap between laboratory and clinical applications, making it an essential platform for researchers, academics, and healthcare professionals committed to the forefront of genetic innovation. Although it does not currently offer open access options, its reputation for rigorous peer review ensures that all published work meets the highest academic standards, providing a reliable reference for scientific inquiry in the United States and beyond. As the field rapidly evolves, the Journal of Gene Medicine remains at the helm, guiding future discoveries with its influential publications and comprehensive insights.

Molecular Therapy Oncolytics is an esteemed Open Access journal published by CELL PRESS, focusing on cutting-edge research in the fields of oncology, molecular medicine, and pharmacology. Established in 2014, the journal has quickly gained a prominent position in the academic community, reflected in its impressive Q1 and Q2 rankings across various categories including Cancer Research, Molecular Medicine, and Pharmacology. With an impactful presence in the UK and a strong international readership, it aims to disseminate significant advancements in therapeutic strategies targeted at cancer treatment and management. By providing a platform for peer-reviewed research, Molecular Therapy Oncolytics plays a critical role in bridging the gap between scientific innovation and clinical application, making it an invaluable resource for researchers, healthcare professionals, and students striving to contribute to the evolving landscape of oncology.

Seminars in Immunopathology is a premier academic journal published by SPRINGER HEIDELBERG, focusing on the intricate relationships between immune responses and pathologies. With an ISSN of 1863-2297 and an E-ISSN of 1863-2300, this journal delivers cutting-edge research and insights to its readers, contributing significantly to the fields of immunology and allergy, as reflected in its Q1 quartile ranking in both categories for 2023. Positioned in a highly competitive niche, it ranks #18 out of 233 in Immunology and Allergy and #22 out of 236 in Immunology and Microbiology, highlighting its impact within the scientific community. Seminars in Immunopathology publishes comprehensive reviews and research articles, aiming to advance understanding of immune mechanisms in disease and promote interdisciplinary collaboration. Accessible from Germany, this journal is a vital resource for researchers, clinicians, and students seeking to stay at the forefront of immunological advancements and therapeutic innovations.

Advanced Therapeutics, published by WILEY in the United Kingdom, stands at the forefront of medical and pharmaceutical research, offering invaluable insights from 2018 to 2024. This distinguished journal, with an E-ISSN of 2366-3987, is recognized for its exceptional academic rigor, boasting an impressive array of Q1 categorizations in essential fields such as Biochemistry (medical), Pharmaceutical Science, and Pharmacology. With its strategic focus on interdisciplinary studies and cutting-edge therapeutic developments, Advanced Therapeutics serves as a vital resource for researchers, professionals, and students keen on advancing their knowledge and contributing to the evolving landscape of medicine and genetics. The journal's high Scopus rankings further affirm its impact, with significant placements in multiple categories underscoring the quality of published research. Although the journal operates under a subscription model, its accessibility to high-impact findings ensures that it remains a pivotal platform for innovative discourse in therapeutics.

Trends in Cancer is a leading journal published by CELL PRESS, dedicated to advancing the field of cancer research and oncology. Since its inception in 2015, the journal has rapidly gained a reputation for excellence, securing both Q1 rankings in Cancer Research and Oncology categories for 2023 and boasting impressive Scopus ranks—#13 out of 404 in Medicine Oncology and #9 out of 230 in Biochemistry, Genetics and Molecular Biology, thus placing it in the top 4% of its field. The journal aims to publish high-quality, innovative research that offers new insights into cancer biology and treatment strategies. With a commitment to scholarly rigor and a broad scope that encompasses molecular mechanisms to therapeutic approaches, Trends in Cancer serves as an essential resource for researchers, professionals, and students eager to stay informed about the latest developments in cancer science. Although it is not an open-access journal, its contributions are pivotal in shaping the future of cancer research.

Cancer Immunology Research is a leading journal dedicated to the rapidly evolving field of cancer immunology, published by the American Association for Cancer Research. Established in 2013, this prestigious journal has quickly made a significant impact in its domain, achieving a 2023 Q1 ranking in both Cancer Research and Immunology. With an impressive Scopus rank of 24 out of 230 in cancer research and 28 out of 236 in immunology, it occupies a valuable position for researchers, professionals, and students engaged in cutting-edge cancer studies. Although it does not offer open access, the journal is committed to disseminating high-quality, peer-reviewed research that advances our understanding of the immune system’s role in cancer. The journal's objectives include fostering innovative studies, enhancing collaboration across disciplines, and promoting the translation of research findings into clinical applications, making it a vital resource for anyone invested in cancer therapy and immunological research.